Germany: BfArM and PEI issued supplementary recommendations on management of clinical trials during COVID-19 pandemic

2024-02-26T11:08:52+00:00May 22nd, 2020|Categories: Clinical Trial, Covid-19, Europe, Regulatory|Tags: , , , , , |

BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) and PEI (Paul-Ehrlich-Institut) provided supplementary recommendations to the guideline on management of clinical trials during COVID-19 released by the European authorities on 20th March 2020. Key points of BfArM and PEI recommendations on [...]

Germany: DIMDI merges into BfArM

2024-02-26T11:15:21+00:00May 20th, 2020|Categories: Europe, Regulatory, Western Europe|Tags: , , , , , , |

DIMDI (Deutsche Institut für Medizinische Dokumentation und Information) and BfArM (Federal Institute for Drugs and Medical Devices) will join to become one agency on May 26th, 2020. Once DIMDI is merged into BfArM, the name that has been in [...]

Go to Top